Orthofix Medical Inc.
OFIX · NASDAQ Global Select · USD
7,90USD
+0,03 (+0,38 %)Stand 9. Nov., 21:00
Nachbörslich7,900,00 (0,00 %)19:30 ET
Kennzahlen
- Eröffnung
- 7,01
- Vortag
- 7,87
- Tagesspanne
- 6,52 – 8,03
- 52 Wochen
- 6,52 – 16,42
- Volumen
- 2,69 Mio.
- Ø Volumen
- 428.243
- Börsenwert
- 319,33 Mio. $
- KGV
- -7,1
- Gewinn je Aktie (TTM)
- -1,12
- Dividendenrendite
- 0,0 %
- Beta
- 0,6
- Nächste Zahlen
- 23. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 822,31 Mio. | 799,49 Mio. | 746,64 Mio. | 460,71 Mio. | 464,48 Mio. |
| Herstellungskosten | 270,61 Mio. | 253,61 Mio. | 260,37 Mio. | 123,54 Mio. | 114,91 Mio. |
| Bruttogewinn | 551,71 Mio. | 545,89 Mio. | 486,27 Mio. | 337,17 Mio. | 349,57 Mio. |
| Forschung und Entwicklung | 57,11 Mio. | 73,64 Mio. | 80,23 Mio. | 49,07 Mio. | 49,62 Mio. |
| Vertrieb und Verwaltung | 456,39 Mio. | 532,53 Mio. | 530,4 Mio. | 308,78 Mio. | 290,67 Mio. |
| Operatives Ergebnis | −68,47 Mio. | −84,62 Mio. | −139,11 Mio. | −13,27 Mio. | −8,32 Mio. |
| EBITDA | 9,93 Mio. | −18,28 Mio. | −79,49 Mio. | 15,66 Mio. | 21,44 Mio. |
| Nettogewinn | −92,19 Mio. | −126 Mio. | −151,4 Mio. | −19,75 Mio. | −38,38 Mio. |
| Gewinn je Aktie (verwässert) | -2,28 | -3,30 | -4,12 | -0,98 | -1,95 |
Umsatz nach Segment
Produkte · FY 2025
- Global Spine687,66 Mio. $100,00 %+1,83 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- Other Countries76,73 Mio. $61,43 %+15,57 %
- ITALY22,28 Mio. $17,83 %+6,08 %
- FRANCE11,96 Mio. $9,57 %−10,65 %
- GERMANY9,11 Mio. $7,29 %
- BRAZIL4,84 Mio. $3,87 %−15,26 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -7,1
- Kurs-Umsatz-Verhältnis
- 0,4
- Kurs-Buchwert-Verhältnis
- 0,8
- PEG
- -0,1
- Bruttomarge
- 69,2 %
- Operative Marge
- −0,8 %
- Nettomarge
- −5,4 %
- Verschuldungsgrad
- 0,5
- EV/EBITDA
- 4,9
- Eigenkapitalrendite
- −10,3 %
- Kapitalrendite (ROIC)
- −1,0 %
- Free-Cashflow-Rendite
- −13,7 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 67,1 % | 68,3 % | 65,1 % | 73,2 % | 75,3 % |
| Operative Marge | −8,3 % | −10,6 % | −18,6 % | −2,9 % | −1,8 % |
| Nettomarge | −11,2 % | −15,8 % | −20,3 % | −4,3 % | −8,3 % |
| KGV | -6,6 | -5,3 | -3,3 | -20,9 | -15,9 |
| Kurs-Umsatz-Verhältnis | 0,7 | 0,8 | 0,7 | 0,9 | 1,3 |
| Kurs-Buchwert-Verhältnis | 1,3 | 1,3 | 0,8 | 1,2 | 1,8 |
| Verschuldungsgrad | 0,5 | 0,4 | 0,2 | 0,1 | 0,1 |
| Liquidität 3. Grades | 2,4 | 2,6 | 2,5 | 3,1 | 2,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 751,86 Mio. | 762,21 Mio. | 579,08 Mio. | 383,48 Mio. | 548,65 Mio. |
| EV/EBITDA | 75,7 | -41,7 | -7,3 | 24,5 | 25,6 |
| Eigenkapitalrendite | −20,5 % | −25,0 % | −25,3 % | −5,9 % | −11,4 % |
| Kapitalrendite (ROIC) | −10,0 % | −11,6 % | −18,2 % | −3,5 % | −2,2 % |
| Free-Cashflow-Rendite | −0,2 % | −1,4 % | −21,8 % | −8,4 % | −0,2 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +2,9 % | +7,1 % | +62,1 % | −0,8 % | +14,2 % |
| Bruttogewinn | +1,1 % | +12,3 % | +44,2 % | −3,5 % | +14,7 % |
| Operatives Ergebnis | +19,1 % | +39,2 % | −948,5 % | −59,6 % | −32,7 % |
| Nettogewinn | +26,8 % | +16,8 % | −666,6 % | +48,5 % | −1.624,8 % |
| Gewinn je Aktie | +30,9 % | +19,9 % | −320,4 % | +49,7 % | −1.600,0 % |
| Freier Cashflow | +85,9 % | +91,6 % | −210,7 % | −3.006,4 % | −102,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 8Kaufen
- 9Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
13,40
Durchschnitt · +69,62 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 851,2 Mio. | 873,64 Mio. | 925,63 Mio. |
| Umsatz (Tief – Hoch) | 849,94 Mio. – 852,72 Mio. | 864,42 Mio. – 882,97 Mio. | 905,22 Mio. – 936,98 Mio. |
| Gewinn je Aktie (Ø) | -1,18 | -0,95 | -0,64 |
| Gewinn je Aktie (Tief – Hoch) | -1,18 – -1,16 | -0,95 – -0,93 | -0,79 – -0,49 |
| Analysten | 1 | 1 | 2 |
Letzte Änderungen
- Canaccord Genuity10. Aug. 2026Buy
- Barrington Research6. Juli 2026Outperform
- Barrington Research22. Mai 2026Outperform
- Stifel22. Mai 2026Buy
- Canaccord Genuity22. Mai 2026Buy
- Barrington Research10. Apr. 2026Outperform
- Stifel9. März 2026Buy
- Canaccord Genuity26. Feb. 2026Buy
Quartalszahlen
Nächste Zahlen: 23. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,27 | -0,41 | -0,68 | -0,19 | 0,12 | -0,44 | -0,38 | 0,03 |
| Gewinn je Aktie · Tatsächlich | -0,15 | -0,39 | -0,52 | -0,06 | -0,57 | -0,36 | -1,35 | -0,75 |
| Abweichung | +43,40 % | +4,85 % | +23,53 % | +70,79 % | −575,00 % | +18,18 % | −255,26 % | −2.600,00 % |
| Umsatz · Tatsächlich | 207,86 Mio. | 210,93 Mio. | 196,71 Mio. | 219,91 Mio. | 205,63 Mio. | 200,7 Mio. | 193,65 Mio. | 215,7 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 94,39 %
- Investoren mit 13F-Meldung
- 142
Größte Investoren
- ENGINE CAPITAL MANAGEMENT, LP11,19 %4,58 Mio.
- JUNIPER INVESTMENT COMPANY, LLC10,86 %4,44 Mio.
- RUBRIC CAPITAL MANAGEMENT LP9,10 %3,72 Mio.
- BLACKROCK, INC.8,13 %3,33 Mio.
- PARADIGM CAPITAL MANAGEMENT INC/NY8,07 %3,3 Mio.
- ARMISTICE CAPITAL, LLC7,98 %3,26 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,23 %1,73 Mio.
- GEODE CAPITAL MANAGEMENT, LLC2,56 %1,05 Mio.
Insider-Geschäfte
- Fisher Patrick2. Nov. 2026 · officer: President, Global Limb ReconVerkauf150 Aktien · 9,07
- Fisher Patrick1. Okt. 2026 · officer: President, Global Limb ReconVerkauf150 Aktien · 9,44
- Juniper Investment Company, LLC21. Sept. 2026 · 10 percent ownerKauf190.000 Aktien · 8,8599
- Juniper Investment Company, LLC21. Sept. 2026 · 10 percent ownerKauf190.000 Aktien · 8,8599
- Juniper Investment Company, LLC18. Sept. 2026 · 10 percent ownerKauf120.000 Aktien · 8,7393
- Juniper Investment Company, LLC18. Sept. 2026 · 10 percent ownerKauf120.000 Aktien · 8,7393
- Fisher Patrick1. Sept. 2026 · officer: President, Global Limb ReconVerkauf150 Aktien · 9,39
- Fisher Patrick18. Aug. 2026 · officer: President, Global Limb ReconVerkauf1295 Aktien · 10,09
Vergleichbare Unternehmen
ABSIAbsci Corporation10,80+6,19 %
AVNSAvanos Medical, Inc.24,99+0,04 %
BFLYButterfly Network, Inc.6,67+4,71 %
DRIODarioHealth Corp.2,06−13,26 %
ESPREsperion Therapeutics, Inc.3,180,00 %
LABStandard BioTools Inc.0,6942+9,15 %
MLTXMoonLake Immunotherapeutics12,62+9,45 %
PACBPacific Biosciences of California, Inc.2,36+4,66 %
Über das Unternehmen
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Führung
- Massimo CalafiorePresident, Chief Executive Officer & Director
- J. Andres CedronChief Legal Officer & Corporate Secretary
- Patrick FisherPresident of Global Biologics & Limb Reconstruction
- Julie AndrewsChief Financial Officer
- Aviva McPherronPresident of Global Operations & Quality
- Geoffrey C. GillespieChief Accounting Officer
- CEO
- Massimo Calafiore
- Mitarbeitende
- 1.605
- Hauptsitz
- Lewisville, TX, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 24. Apr. 1992
- Website
- orthofix.com
Nachrichten
- MarketBeat · 9. Nov., 12:17Orthofix Medical Q3 Earnings Call Highlights
- Seeking Alpha · 9. Nov., 11:31Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 9. Nov., 9:41Orthofix (OFIX) Surpasses Q3 Earnings Estimates
- Business Wire · 9. Nov., 7:00Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance
- Zacks Investment Research · 5. Nov., 8:51Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?
- Business Wire · 23. Okt., 16:00Orthofix to Report Third Quarter 2026 Financial Results
- PRNewsWire · 21. Okt., 16:18SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)
- PRNewsWire · 13. Okt., 15:12Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- PRNewsWire · 8. Okt., 19:35SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)
- MarketBeat · 15. Aug., 22:02Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.